Clinical trial · Interventional
Vaccine Therapy in Treating Patients With Advanced Kidney Cancer
A Phase I Pilot Trial of a Multi-Antigen Loaded Dendritic Cell Vaccine for the Treatment of Advanced Renal Cell Carcinoma
NCT00004880CI-TRIAL-00046375completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have advanced kidney cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Kidney Cancer | Malignant Kidney Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| conventional surgery | Procedure | — | UNRESOLVED |
| dendritic cell vaccine therapy | Biological | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed metastatic renal cell carcinoma Evaluable or bidimensionally measurable disease with primary renal tumor in place or surgically accessible metastatic site greater than 2 x 2 cm * Over 18 * ECOG 0-1 * Hematopoietic: * Hemoglobin at least 10 g/dL (not transfusion dependent) * Platelet count at least 75,000/mm3 * WBC greater than 3,000/mm3 * Hepatic: SGOT/SGPT no greater than 5 times upper limit of normal (ULN) * Alkaline phosphatase no greater than 5 times ULN * PT/PTT no greater than 1.5 times ULN * Bilirubin no greater than 2.5 mg/dL * Renal: Creatinine no greater than 2.0 g/dL * Hepatitis B surface antigen negative * Negative pregnancy test * Fertile patients must use effective contraception * At least 4 weeks since prior immunotherapy * At least 4 weeks since prior chemotherapy * At least 4 weeks since prior radiotherapy * At least 14 days since prior acute therapy for infection Exclusion Criteria: * uncontrolled CNS metastasis * ischemic heart disease that precludes surgery * pulmonary condition that precludes surgery * other underlying condition or allergy that would preclude study * acute viral, bacterial, or fungal infection requiring therapy HIV negative * pregnant or nursing * other acute medical problems that would preclude study * concurrent corticosteroids (oral, topical, inhaled) * prior organ allografts
References
Publications (0)
Data not yet available
No reference posted for this study.